Gilead’s 2026 Shopping Spree Continues With Tubulis Buyout

 
• By Alaric DeArment
  
Gilead is spending up to $5bn to acquire privately held German biotech Tubulis. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business